WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year

Core Insights - WuXi Biologics has received a Platinum Award from The Asset ESG Corporate Awards for the fourth consecutive year, highlighting its commitment to sustainable practices and innovation through green technology [1][2][3] ESG Recognition - The Asset evaluates companies on various ESG metrics, and WuXi Biologics is the only healthcare company recognized in this year's awards [2] - The company has achieved an "AAA" rating from MSCI ESG Ratings and has been awarded the Platinum Medal by EcoVadis, among other recognitions [4] Leadership and Commitment - Dr. Chris Chen, CEO of WuXi Biologics, emphasized the award as a motivation to continue advancing sustainability efforts in the biologics CRDMO industry [3] - WuXi Biologics aligns its initiatives with the United Nations Sustainable Development Goals and is a signatory to the UN Global Compact and the Science Based Targets initiative [3][7] Operational Overview - WuXi Biologics employs over 12,000 skilled workers across multiple countries and supports 742 integrated client projects, including 16 in commercial manufacturing as of June 30, 2024 [6] - The company aims to be an ESG leader in the biologics CRDMO sector, utilizing next-generation biomanufacturing technologies and clean energy sources [7]